Characteristics Associated with Lung Function Trajectories: An Analysis of the SPIROMICS Cohort.

Buhr RG, Jackson NJ, Fazio JC, Barjaktarevic I, Bateman LA, Bhatt SP, Couper DJ, Curtis JL, Dolezal BA, Drummond MB, Han MK, Hansel NN, Iyer AS, Krishnan JA, Martinez FJ, Ohar J, Paine R, Rennard SI, Smith BM, Tashkin DP, Woodruff PG, Anderson WH, Cooper CB. Characteristics Associated with Lung Function Trajectories: An Analysis of the SPIROMICS Cohort. Annals of the American Thoracic Society. 2025 Apr 8 DOI: 10.1513/AnnalsATS.202405-500OC.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

RATIONALE: Discovering the biological basis of progression in chronic obstructive pulmonary disease (COPD), especially of rapid decline (RD) in FEV1, is essential to develop precision therapies. OBJECTIVES: First, to define baseline characteristic of RD ( = 100 mL/year), relative to those who were stable-to-improved (S/I) or with intermediate decline (D)-categories based on spirometric data from the Framingham Offspring Cohort. Second, to examine these categories as predictors of longitudinal COPD outcomes, adjusting for baseline characteristics. METHODS: Among ever-smoking SPIROMICS participants with = 2 spirometric measurements over 8 years, we fit slopes of postbronchodilator FEV1 change by linear regression. We used ordinal regression, testing baseline characteristics as predictors of lung function change categories (S/I, D and RD) and used those categories to assess associated clinical outcomes. MEASUREMENTS AND MAIN RESULTS: In this heavy smoking cohort ( = 20 pack-years), there were 747 S/I (40%) and 336 RD (18%). In adjusted models of baseline factors associated with trajectories of decline, steeper decline was associated with better initial lung function (all P < 0.001) and greater likelihood of baseline bronchodilator responsiveness (S/I, D, RD: 32%, 37%, 43%; P < 0.001); no association between RD and race, ethnicity, socioeconomic status, medical history, or respiratory medication use. Regarding clinical endpoints, RD was associated with greater symptom burden, worse health-related quality of life and increased mortality, but not exacerbation frequency. CONCLUSION: Categorical definitions of S/I and RD highlight bronchodilator responsiveness and smoking as risks for adverse outcomes, including death. Contrasting these disease trajectories will support the future identification of the biological bases of COPD progression.